CARMUSTINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C5H9Cl2N3O2
Molecular Weight	214.0499
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C(CN=C(N(CCCl)N=O)O)Cl

InChI

InChIKey=DLGOEMSEDOSKAD-UHFFFAOYSA-N

InChI=1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11)

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017422s046lbl.pdf
Curator's Comment:: description was created based on several sources, including: https://www.drugs.com/cdi/carmustine.html http://www.rxlist.com/bicnu-drug.htm http://www.wikidoc.org/index.php/Carmustine_(injection)

Carmustine is a cancer medication that interferes with the growth and spread of cancer cells in the body. Carmustine is used to treat brain tumors, Hodgkin's disease, multiple myeloma, and non-Hodgkin's lymphoma. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross-resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins. Pulmonary toxicity characterized by pulmonary infiltrates and/or fibrosis has been reported to occur from 9 days to 43 months after treatment with BiCNU and related nitrosoureas. A frequent and serious toxicity of BiCNU is delayed myelosuppression. Nausea and vomiting after intravenous administration of BiCNU are noted frequently. Greater myelotoxicity (e.g., leukopenia and neutropenia) has been reported when carmustine was combined with cimetidine.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
DNA 232 Target ID: CHEMBL2311221 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017422s046lbl.pdf \| http://www.drugbank.ca/drugs/DB00262	Inhibitor 7728	57.0 µM [IC50]
RNA 17 Target ID: CHEMBL2311222 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017422s046lbl.pdf \| http://www.drugbank.ca/drugs/DB00262	Inhibitor 7728
Glutathione reductase 10 Target ID: CHEMBL2755 Sources: http://www.drugbank.ca/drugs/DB00262 \| https://www.ncbi.nlm.nih.gov/pubmed/6623510 \| https://www.ncbi.nlm.nih.gov/pubmed/3806383 \| https://www.ncbi.nlm.nih.gov/pubmed/15321730	Inhibitor 7728	1.6 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Glioblastoma 55 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017422s046lbl.pdf	Primary	Approved 8043	BICNU Approved Use GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1) Launch Date 2.26540798E11
Medulloblastoma 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017422s046lbl.pdf	Primary	Approved 8043	BICNU Approved Use GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1) Launch Date 2.26540798E11
Astrocytoma 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017422s046lbl.pdf	Primary	Approved 8043	BICNU Approved Use GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1) Launch Date 2.26540798E11
Ependymoma 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017422s046lbl.pdf	Primary	Approved 8043	BICNU Approved Use GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1) Launch Date 2.26540798E11
Multiple myeloma 145 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017422s046lbl.pdf	Primary	Approved 8043	BICNU Approved Use GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1) Launch Date 2.26540798E11
Hodgkin's lymphoma 34 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017422s046lbl.pdf	Secondary	Approved 8043	BICNU Approved Use GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1) Launch Date 2.26540798E11
Non-Hodgkin's lymphoma 74 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017422s046lbl.pdf	Secondary	Approved 8043	BICNU Approved Use GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1) Launch Date 2.26540798E11

C_max

Value	Dose	Co-administered	Analyte	Population
3.7 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/15077226	600 mg/m² 1 times / day steady-state, intravenous dose: 600 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: Cyclophosphamide \| Cisplatin	Cyclophosphamide \| Cisplatin	CARMUSTINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7.8 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3719578	1000 mg/m² single, intravenous dose: 1000 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:		CARMUSTINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
456 μg × min/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/15077226	600 mg/m² 1 times / day steady-state, intravenous dose: 600 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: Cyclophosphamide \| Cisplatin	Cyclophosphamide \| Cisplatin	CARMUSTINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
538 μM × min EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3719578	1000 mg/m² single, intravenous dose: 1000 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:		CARMUSTINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
18 min EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/15077226	600 mg/m² 1 times / day steady-state, intravenous dose: 600 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: Cyclophosphamide \| Cisplatin	Cyclophosphamide \| Cisplatin	CARMUSTINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
23% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3719578	1000 mg/m² single, intravenous dose: 1000 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:		CARMUSTINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
150 mg/m2 1 times / 7 weeks multiple, intravenous MTD Dose: 150 mg/m2, 1 times / 7 weeks Route: intravenous Route: multiple Dose: 150 mg/m2, 1 times / 7 weeks Co-administed with:: IFN-a, s.c(12 x 10(6) units/m2; Days 1-3 each week of a 7-week cycle.) Sources: https://pubmed.ncbi.nlm.nih.gov/9457812 Page: p.299, 300	unhealthy, 26-66 n = 11 Health Status: unhealthy Condition: Glioma Age Group: 26-66 Sex: M+F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/9457812 Page: p.299, 300	DLT: Leukopenia, Thrombocytopenia... Disc. AE: Pulmonary toxicity... Dose limiting toxicities: Leukopenia (grade 3-4, 45%) Thrombocytopenia (grade 3-4, 27%) AEs leading to discontinuation/dose reduction: Pulmonary toxicity (9%) Sources: https://pubmed.ncbi.nlm.nih.gov/9457812 Page: p.299, 300
125 mg/m2 1 times / 6 weeks multiple, intravenous MTD Dose: 125 mg/m2, 1 times / 6 weeks Route: intravenous Route: multiple Dose: 125 mg/m2, 1 times / 6 weeks Co-administed with:: streptozocin, i.v(2 g/m2, single) Sources: https://pubmed.ncbi.nlm.nih.gov/1531148 Page: p.258	unhealthy, 31-79 n = 24 Health Status: unhealthy Condition: Advanced cancer Age Group: 31-79 Sex: M+F Population Size: 24 Sources: https://pubmed.ncbi.nlm.nih.gov/1531148 Page: p.258	DLT: Thrombocytopenia... Disc. AE: Adult respiratory distress syndrome... Dose limiting toxicities: Thrombocytopenia (grade 3-4) AEs leading to discontinuation/dose reduction: Adult respiratory distress syndrome (grade 5, 4.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/1531148 Page: p.258
200 mg/m2 1 times / 6 weeks multiple, intravenous (max) Recommended Dose: 200 mg/m2, 1 times / 6 weeks Route: intravenous Route: multiple Dose: 200 mg/m2, 1 times / 6 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Brain tumors\| Multiple myeloma\| Hodgkin's lymphoma\| Non-Hodgkin's lymphomas Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1	Disc. AE: Marrow depression of, Thrombocytopenia... AEs leading to discontinuation/dose reduction: Marrow depression of Thrombocytopenia Leukopenia Pulmonary toxicity Administration site extravasation Carcinogenicity Fetal damage Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Pulmonary toxicity	9% Disc. AE	150 mg/m2 1 times / 7 weeks multiple, intravenous MTD Dose: 150 mg/m2, 1 times / 7 weeks Route: intravenous Route: multiple Dose: 150 mg/m2, 1 times / 7 weeks Co-administed with:: IFN-a, s.c(12 x 10(6) units/m2; Days 1-3 each week of a 7-week cycle.) Sources: https://pubmed.ncbi.nlm.nih.gov/9457812 Page: p.299, 300	unhealthy, 26-66 n = 11 Health Status: unhealthy Condition: Glioma Age Group: 26-66 Sex: M+F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/9457812 Page: p.299, 300
Thrombocytopenia	grade 3-4, 27% DLT	150 mg/m2 1 times / 7 weeks multiple, intravenous MTD Dose: 150 mg/m2, 1 times / 7 weeks Route: intravenous Route: multiple Dose: 150 mg/m2, 1 times / 7 weeks Co-administed with:: IFN-a, s.c(12 x 10(6) units/m2; Days 1-3 each week of a 7-week cycle.) Sources: https://pubmed.ncbi.nlm.nih.gov/9457812 Page: p.299, 300	unhealthy, 26-66 n = 11 Health Status: unhealthy Condition: Glioma Age Group: 26-66 Sex: M+F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/9457812 Page: p.299, 300
Leukopenia	grade 3-4, 45% DLT	150 mg/m2 1 times / 7 weeks multiple, intravenous MTD Dose: 150 mg/m2, 1 times / 7 weeks Route: intravenous Route: multiple Dose: 150 mg/m2, 1 times / 7 weeks Co-administed with:: IFN-a, s.c(12 x 10(6) units/m2; Days 1-3 each week of a 7-week cycle.) Sources: https://pubmed.ncbi.nlm.nih.gov/9457812 Page: p.299, 300	unhealthy, 26-66 n = 11 Health Status: unhealthy Condition: Glioma Age Group: 26-66 Sex: M+F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/9457812 Page: p.299, 300
Thrombocytopenia	grade 3-4 DLT	125 mg/m2 1 times / 6 weeks multiple, intravenous MTD Dose: 125 mg/m2, 1 times / 6 weeks Route: intravenous Route: multiple Dose: 125 mg/m2, 1 times / 6 weeks Co-administed with:: streptozocin, i.v(2 g/m2, single) Sources: https://pubmed.ncbi.nlm.nih.gov/1531148 Page: p.258	unhealthy, 31-79 n = 24 Health Status: unhealthy Condition: Advanced cancer Age Group: 31-79 Sex: M+F Population Size: 24 Sources: https://pubmed.ncbi.nlm.nih.gov/1531148 Page: p.258
Adult respiratory distress syndrome	grade 5, 4.2% Disc. AE	125 mg/m2 1 times / 6 weeks multiple, intravenous MTD Dose: 125 mg/m2, 1 times / 6 weeks Route: intravenous Route: multiple Dose: 125 mg/m2, 1 times / 6 weeks Co-administed with:: streptozocin, i.v(2 g/m2, single) Sources: https://pubmed.ncbi.nlm.nih.gov/1531148 Page: p.258	unhealthy, 31-79 n = 24 Health Status: unhealthy Condition: Advanced cancer Age Group: 31-79 Sex: M+F Population Size: 24 Sources: https://pubmed.ncbi.nlm.nih.gov/1531148 Page: p.258
Administration site extravasation	Disc. AE	200 mg/m2 1 times / 6 weeks multiple, intravenous (max) Recommended Dose: 200 mg/m2, 1 times / 6 weeks Route: intravenous Route: multiple Dose: 200 mg/m2, 1 times / 6 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Brain tumors\| Multiple myeloma\| Hodgkin's lymphoma\| Non-Hodgkin's lymphomas Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1
Carcinogenicity	Disc. AE	200 mg/m2 1 times / 6 weeks multiple, intravenous (max) Recommended Dose: 200 mg/m2, 1 times / 6 weeks Route: intravenous Route: multiple Dose: 200 mg/m2, 1 times / 6 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Brain tumors\| Multiple myeloma\| Hodgkin's lymphoma\| Non-Hodgkin's lymphomas Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1
Fetal damage	Disc. AE	200 mg/m2 1 times / 6 weeks multiple, intravenous (max) Recommended Dose: 200 mg/m2, 1 times / 6 weeks Route: intravenous Route: multiple Dose: 200 mg/m2, 1 times / 6 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Brain tumors\| Multiple myeloma\| Hodgkin's lymphoma\| Non-Hodgkin's lymphomas Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1
Leukopenia	Disc. AE	200 mg/m2 1 times / 6 weeks multiple, intravenous (max) Recommended Dose: 200 mg/m2, 1 times / 6 weeks Route: intravenous Route: multiple Dose: 200 mg/m2, 1 times / 6 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Brain tumors\| Multiple myeloma\| Hodgkin's lymphoma\| Non-Hodgkin's lymphomas Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1
Marrow depression of	Disc. AE	200 mg/m2 1 times / 6 weeks multiple, intravenous (max) Recommended Dose: 200 mg/m2, 1 times / 6 weeks Route: intravenous Route: multiple Dose: 200 mg/m2, 1 times / 6 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Brain tumors\| Multiple myeloma\| Hodgkin's lymphoma\| Non-Hodgkin's lymphomas Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1
Pulmonary toxicity	Disc. AE	200 mg/m2 1 times / 6 weeks multiple, intravenous (max) Recommended Dose: 200 mg/m2, 1 times / 6 weeks Route: intravenous Route: multiple Dose: 200 mg/m2, 1 times / 6 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Brain tumors\| Multiple myeloma\| Hodgkin's lymphoma\| Non-Hodgkin's lymphomas Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1
Thrombocytopenia	Disc. AE	200 mg/m2 1 times / 6 weeks multiple, intravenous (max) Recommended Dose: 200 mg/m2, 1 times / 6 weeks Route: intravenous Route: multiple Dose: 200 mg/m2, 1 times / 6 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Brain tumors\| Multiple myeloma\| Hodgkin's lymphoma\| Non-Hodgkin's lymphomas Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3423	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3423
ChemicalBook	CB0449612	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0449612
MolPort	MolPort-003-665-505	https://www.molport.com/shop/molecule-link/MolPort-003-665-505
ZINC	ZINC000003830387	http://zinc15.docking.org/substances/ZINC000003830387
eMolecules	535644	https://www.emolecules.com/cgi-bin/more?vid=535644

PubMed

Title	Date	PubMed
Primary Central Nervous System Tumors in Adults.	1999 Nov	11096723
Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.	2000 Oct 1	11034089
Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.	2001	11669219
Inducible nitric oxide synthase neutralizes carbamoylating potential of 1,3-bis(2-chloroethyl)-1-nitrosourea in c6 glioma cells.	2001 Apr	11259558
Temozolomide in combination with other cytotoxic agents.	2001 Aug	11550136
Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU.	2001 Aug	11445852
Induction of lacI mutations in Big Blue Rat-2 cells treated with 1-(2-hydroxyethyl)-1-nitrosourea: a model system for the analysis of mutagenic potential of the hydroxyethyl adducts produced by 1,3-bis (2-chloroethyl)-1-nitrosourea.	2001 Dec 12	11733074
Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).	2001 Feb	11426523
Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisone.	2001 Feb	11253603
Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.	2001 Feb	11234899
Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia.	2001 Feb 15	11181679
Low infectious morbidity after intensive chemotherapy and autologous peripheral blood progenitor cell transplantation in the outpatient setting for women with breast cancer.	2001 Feb 15	11181116
Antitumor efficacy of SarCNU in a human glioma xenograft model expressing both MGMT and extraneuronal monoamine transporter.	2001 Jan	11349876
Anticancer drug-induced kidney disorders.	2001 Jan	11219485
Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.	2001 Jan	11168503
Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study.	2001 Jan 3	11136838
Detecting treatment-by-centre interaction in multi-centre clinical trials.	2001 Jan 30	11169597
Amifostine does not protect malignant lymphoma cell lines from the cytotoxic effects of various chemotherapeutics in vitro.	2001 Jul	11699416
Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?	2001 Jul	11529465
Acyl derivatives of demethylpenclomedine, an antitumor-active, non-neurotoxic metabolites of penclomedine.	2001 Jul	11488524
A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells.	2001 Jul 1	11431370
Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS.	2001 Jul 10	11445629
A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma.	2001 Jul 15	11466698
Diaminopurine-acridine heterodimers for specific recognition of abasic site containing DNA. Influence on the biological activity of the position of the linker on the purine ring.	2001 Jul 23	11459646
Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study.	2001 Jun	11417474
Heterogeneous methylation of the O(6)-methylguanine-DNA methyltransferase promoter in immortalized IMR90 cell lines.	2001 Jun	11351250
Pharmacodynamics of high-dose chemotherapy.	2001 Mar	11465151
Inactivation of human O(6)-alkylguanine-DNA alkyltransferase by modified oligodeoxyribonucleotides containing O(6)-benzylguanine.	2001 Mar	11181929
Protection of mammalian cells against chemotherapeutic agents thiotepa, 1,3-N,N'-bis(2-chloroethyl)-N-nitrosourea, and mafosfamide using the DNA base excision repair genes Fpg and alpha-hOgg1: implications for protective gene therapy applications.	2001 Mar	11181913
Both extraneuronal monoamine transporter and O(6)-methylguanine-DNA methyltransferase expression influence the antitumor efficacy of 2-chloroethyl-3-sarcosinamide- 1-nitrosourea in human tumor xenografts.	2001 Mar	11181897
The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.	2001 Mar 1	11229339
The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.	2001 Mar 1	11229336
Debenzylation of O(6)-benzyl-8-oxoguanine in human liver: implications for O(6)-benzylguanine metabolism.	2001 Mar 15	11266657
[Intracytoplasmic crystals and Fanconi syndrome in a patient with IgA kappa myeloma].	2001 Mar-Apr	11464657
Long-term results of a phase-II-pilot trial on preoperative high-dose chemotherapy with stem cell rescue in patients with cancer of the upper gastrointestinal tract.	2001 Mar-Apr	11182052
Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis.	2001 May	11377494
Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents.	2001 May	11350911
Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice.	2001 May 15	11358820
Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.	2001 Nov 15	11698273
Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.	2001 Oct	11704790
Outcome and long-term side effects after synchronous radiochemotherapy for childhood brain stem gliomas.	2001 Oct	11694794
G156A MGMT-transduced human mesenchymal stem cells can be selectively enriched by O6-benzylguanine and BCNU.	2001 Oct	11672516
Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.	2001 Oct	11595684
Levels of N7-(2-hydroxyethyl)guanine as a molecular dosimeter of drug delivery to human brain tumors.	2001 Oct	11584893
T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement.	2001 Sep	11552988
Accelerated hazards regression model and its adequacy for censored survival data.	2001 Sep	11550937
Use of pure t-butanol as a solvent for freeze-drying: a case study.	2001 Sep 11	11532568
Up-regulation of K(+) channels in diabetic rat ventricular myocytes by insulin and glutathione.	2002 Jan	11744015
Escherichia coli FPG and human OGG1 reduce DNA damage and cytotoxicity by BCNU in human lung cells.	2002 Jan	11741815

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose of BiCNU as a single agent in previously untreated patients is 150 to 200 mg/m2 intravenously every 6 weeks. This may be given as a single dose or divided into daily injections such as 75 to 100 mg/m2 on 2 successive days.

Route of Administration: Other

In Vitro Use Guide

LD50 values for the short term glioma tumour cultures lay in the range 10 - 90 μg/ml for Carmustine.

Name

Type

Language

CARMUSTINE

Official Name

English

GLIADEL

Brand Name

English

SRI-1720

Code

English

BISCHLOROETHYL NITROSOUREA [IARC]

Common Name

English

CARMUSTINE [JAN]

Common Name

English

DTI-015

Code

English

CARMUSTINE [EP MONOGRAPH]

Common Name

English

SK-27702

Code

English

CARMUSTINE [MI]

Common Name

English

CARMUSTINE [INN]

Common Name

English

CARMUSTINE [USAN]

Common Name

English

CARMUSTINE [WHO-DD]

Common Name

English

CARMUSTINE [MART.]

Common Name

English

UREA, N,N'-BIS(2-CHLOROETHYL)-N-NITROSO-

Systematic Name

English

CARMUSTINE [USP MONOGRAPH]

Common Name

English

CAMUSTINE [VANDF]

Common Name

English

CARMUSTINE [HSDB]

Common Name

English

BICNU

Brand Name

English

CARMUBRIS

Brand Name

English

NSC-409962

Code

English

CARMUSTINE [EP]

Common Name

English

FDA-0345

Code

English

BCNU

Code

English

CARMUSTINE [USP-RS]

Common Name

English

BECENUN

Brand Name

English

CARMUSTINE [ORANGE BOOK]

Common Name

English

1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C699